CD274 and cancer: Since the process of trastuzumab mediated ADCC involves engaging cancer cells with immune cells leading to the secretion of IFN-γ, the resulting overexpression of PD-L1 is postulated as a possible pathway of drug resistance development against trastuzumab treatment.